Chemical Aftertreatment, E.g., Acylation, Methylation, Etc. Patents (Class 530/345)
  • Patent number: 10300144
    Abstract: The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 125 saccharide units, and wherein the population consists of substantially only N-terminal derivatives of the protein. Typically, the polysaccharide is PSA. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: May 28, 2019
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Rongsheng Zhang
  • Patent number: 9902784
    Abstract: A method of stabilizing a membrane protein includes forming a membrane protein-amphiphilic polymer complex by binding a membrane protein in an aqueous solution to the amphiphilic polymer represented by Formula 1. The amphiphilic polymer includes a large amount of hydrophilic structures and hydrophobic structures, and thereby effectively stabilizing a membrane protein having a hydrophobic surface in an aqueous solution.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: February 27, 2018
    Assignee: Kookmin University Industry Academy Cooperation Foundation
    Inventors: Yeon-Gyu Yu, Moon-Hee Sung
  • Patent number: 9638702
    Abstract: The invention provides methods and kits for detecting conformationally altered proteins and prions in a sample. In one embodiment, the conformationally altered proteins and prions are associated with amyloidogenic diseases.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: May 2, 2017
    Assignee: SYSTEM OF SYSTEMS ANALYTICS, INC.
    Inventors: Cindy Orser, Anne Grosset, Eugene A. Davidson
  • Patent number: 9439974
    Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via an amine group; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two amine groups; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via amine groups in sai
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: September 13, 2016
    Assignee: POLYTHERICS LIMITED
    Inventors: Stephen James Brocchini, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
  • Patent number: 9409929
    Abstract: A (meth)allylsilane compound chemically bonded to various alcohol derivatives including polyol derivatives such as saccharides, is raw material used to cause a substrate to express functionalities such as a defogging property and separation characteristics for column chromatography, can be easily prepared, is easily purified, and is stable and easy to handle, and a functional material in which those functionalities are expressed, while silyl group-containing groups are conveniently carried at a high density on the surface of the substrate, by using the (meth)allylsilane compound as a silane coupling agent for silane-coupling to the substrate. The (meth)allylsilane compound includes a (meth)allylsilyl group-containing alkyl group or a (meth)allylsilylalkyl group-containing aralkyl group that is bonded to an alcohol derivative.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: August 9, 2016
    Assignees: KYOEISHA CHEMICAL CO., LTD., DAICEL CORPORATION
    Inventor: Toyoshi Shimada
  • Patent number: 9327062
    Abstract: The present invention provides an implantable device having a biosoluble coating comprising a polyelectrolyte and a counterion and the methods of making and using the same.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: May 3, 2016
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed F. A. Hossainy, O. Mikael Trollsas, Lothar W. Kleiner
  • Patent number: 9328369
    Abstract: The present invention is aimed to provide a method for industrially producing a useful substance (protein etc.) utilizing a bacterium such as Escherichia coli in the presence of a surfactant and a surfactant to be used in this method for producing a useful substance. The present invention is a method for producing a useful substance into a culture solution by secretion by a bacterium in the culture solution, wherein the culture solution contains a surfactant (A), and a dried cell density based on the volume of the culture solution is 1.5 to 500 g/L. More preferably, the present invention is a method for producing a useful substance wherein the surfactant (A) is at least one agent selected from the group consisting of an amphoteric surfactant, an anionic surfactant, and a nonionic surfactant having an HLB value of 0 to 13.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: May 3, 2016
    Assignee: SANYO CHEMICAL INDUSTRIES, LTD.
    Inventors: Fusamitsu Yanagihara, Shunichiro Yamaguchi
  • Patent number: 9322025
    Abstract: The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: April 26, 2016
    Assignee: Medtronic, Inc.
    Inventors: James A. Williams, Peng Luan, Yuannan Xia, Scott Harley
  • Patent number: 9266934
    Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 23, 2016
    Assignees: The Regents of the University of Colorado, a body corporate, AmideBio, LLC
    Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
  • Patent number: 9090643
    Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 28, 2015
    Assignee: NEWLINK GENETICS CORPORATION
    Inventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
  • Publication number: 20150148525
    Abstract: The invention relates to a polypeptide comprising an amino acid having a bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) group, particularly when said BCN group is present as: a residue of a lysine amino acid. The invention also relates to a method of producing a polypeptide comprising a BCN group, said method comprising genetically incorporating an amino acid comprising a BCN group into a polypeptide. The invention also relates to an amino acid comprising bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN), particularly and amino acid which is bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) lysine. In addition the invention relates to a PylRS tRNA synthetase comprising the mutations Y271M, L274G and C313A.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 28, 2015
    Inventors: Jason Chin, Kathrin Lang
  • Publication number: 20150133634
    Abstract: A kit for producing a radiopharmaceutical, having: a cation exchange cartridge; a reaction vial having a marker precursor; a solution vial having a solvent; an elution vial having a sterile solution including common salt (NaCl) and hydrochloric acid (HCl); and a buffer salt. A method for producing a radiopharmaceutical is also disclosed.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 14, 2015
    Inventor: Dirk Müller
  • Patent number: 9023988
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. Macrocycles of the invention include triazole moieties that crosslink amino acid side chains. The cross links can stabilize a secondary structure of a peptidomimetic macrocycle, such as an ?-helix.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 5, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 9011919
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 21, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Patent number: 9006183
    Abstract: The use of lipopeptides as inducers of NF-?B for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: April 14, 2015
    Assignees: Cleveland Clinic Foundation, Cleveland BioLabs, Inc.
    Inventors: Alexander Shakhov, Andrei Gudkov
  • Patent number: 8999930
    Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 7, 2015
    Assignee: PharmaIN Corporation
    Inventors: Gerardo M. Castillo, Elijah M. Bolotin
  • Patent number: 8969294
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: March 3, 2015
    Assignees: Istituto di Recerche di Biologia Molecolare P. Angeletti S.R.L., Indiana University Research and Technology Corporation
    Inventors: Elisabetta Bianchi, Antonello Pessi, Jonathan Day, Richard Dimarchi, David Smiley
  • Publication number: 20150057433
    Abstract: Reagents are disclosed for chemoselective tagging of methionine residues in peptides and polypeptides, subsequent bioorthogonal tag functionalization, and cleavage of the tags when desired to regenerate unmodified samples. This method compliments other peptide tagging strategies and adds capability for tag removal, which may be useful for release of therapeutic peptides from a carrier, or release of tagged protein digests from solid supports.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 26, 2015
    Applicant: The Regents of the University of California
    Inventors: Timothy J. Deming, Jessica R. Kramer
  • Patent number: 8961985
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: February 24, 2015
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh
  • Patent number: 8956604
    Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 17, 2015
    Assignee: The University of Kansas
    Inventors: Cory Berkland, Joshua Sestak
  • Publication number: 20150037359
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 5, 2015
    Applicant: AMUNIX OPERATING, INC.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • Patent number: 8940867
    Abstract: Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disuifide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: January 27, 2015
    Assignee: Nuovo Biologics, LLC
    Inventors: Kent D. Miller, Billy S. Austin
  • Patent number: 8940690
    Abstract: The present disclosure provides a cross-linked material comprising conjugates which include two or more separate affinity ligands bound to a non-polymeric framework, wherein the molecular weight of the non-polymeric framework is less than 10,000 Da; and multivalent cross-linking agents that non-covalently bind the affinity ligands of the conjugates and thereby cross-link the conjugates to form a cross-linked material, wherein the non-covalent bonds between the multivalent cross-linking agents and the affinity ligands are competitively dissociated in the presence of excess amounts of a target molecule. The present disclosure also provides methods of making and methods of using these materials. In other aspects, the present disclosure provides exemplary conjugates including conjugates for use in glucose responsive cross-linked materials.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: January 27, 2015
    Assignees: National Institutes of Health (NIH), The United States of America Dept. of Health and Human Services (DHHS), The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: Todd C. Zion, Thomas M. Lancaster
  • Publication number: 20150011731
    Abstract: Dye compounds of the formula (1) wherein A is a protective agent group that has a characteristic of modifying the singlet-triplet occupancy of the shown cyanine moiety, and M is a reactive crosslinking group or a group that can be converted to a reactive crosslinking group. Methods for synthesizing the dye compounds and applications for their use are also described.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 8, 2015
    Applicant: CORNELL UNIVERSITY
    Inventors: Scott C. Blanchard, Roger Altman, J. David Warren, Zhou Zhou
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Patent number: 8927500
    Abstract: Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: January 6, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Vincent Guerlavais, Carl Elkin, Huw M. Nash, Tomi K. Sawyer, Bradford J. Graves, Eric Feyfant
  • Publication number: 20140377177
    Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
    Type: Application
    Filed: May 8, 2014
    Publication date: December 25, 2014
    Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
  • Patent number: 8916169
    Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: December 23, 2014
    Assignee: NewLink Genetics Corporation
    Inventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
  • Patent number: 8916683
    Abstract: Described herein are block copolymer conjugates that form double-network hydrogels under appropriate conditions. The conjugates comprise a block of polymer end-group, a block of self-associating peptide or protein, and flexible linkers between the two. Hydrogels comprising the conjugates have the mechanical properties, including elastic modulus and fracture toughness, required for load-bearing applications, while maintaining desirable shear-thinning properties, for example, for injectability.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: December 23, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Bradley D. Olsen, Matthew J. Glassman, Jacqueline Chan
  • Publication number: 20140371432
    Abstract: The present invention provides a double-stranded RNA structure, which comprises a polymer compound covalently bonded to a double-helix oligo RNA useful for the treatment of diseases, particularly cancer, in order to enhance the delivery of the double-helix oligo RNA, and further comprises a target-specific ligand bonded thereto, a preparation method thereof, and a technique of delivering the double-helix oligo RNA in a target-specific manner using the RNA structure. A nanoparticle composed of the ligand-bonded double-helix oligo RNA structures can efficiently deliver the double-helix oligo RNA to a target, and thus can exhibit the activity of the double-helix oligo RNA even when the double-helix oligo RNA is administered at a relatively low concentration. Also, it can prevent the non-specific delivery of the double-helix oligo RNA into other organs and cells.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 18, 2014
    Inventors: Jeiwook Chae, Boram Han, Han-na Kim, Han Oh Park, Pyoung Oh Yoon, Sun Gi Kim, Kwang-Ju Jung, Taewoo Kwon, Jong Deok Choi, Sam Young Lee, Eun-Jung Jung
  • Patent number: 8911967
    Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 16, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Susann Taudte, Walter Scott Willett, Robert J. Bayer, Matthew Kalo
  • Patent number: 8912309
    Abstract: Disclosed is a preparation method for caspofungin, comprising the steps: (a) a compound as represented in Formula 2 and a strong leaving group 5 are mixed to obtain a compound as represented in Formula 3; (b) the compound as represented in Formula 3 and ethylenediamine are mixed to obtain a compound as represented in Formula 4; and, (c) the compound as represented in Formula 4 is mixed with a hydroxyl protection agent, and then a borane complex is mixed in to obtain a compound as represented in Formula 1.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 16, 2014
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
  • Publication number: 20140364587
    Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 11, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Caspar Christensen, Michael Raunjær, Rune Severinsen, Jens C. Norrild
  • Patent number: 8906848
    Abstract: In general, the invention relates to methods of synthesizing AbA derivatives that are useful for treating infection and amenable to further chemical elaboration. These novel methods are scalable for industrial production and employ safer, simpler, and more efficient process conditions. Furthermore, the invention also provides novel compounds and intermediates useful for implementing the methods described herein and/or for the treatment of infection.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 9, 2014
    Assignee: AureoGen Biosciences, inc.
    Inventors: Peter Wuts, Ake P. Elhammer
  • Patent number: 8906850
    Abstract: The present disclosure provides crystalline insulin-conjugates. The present disclosure also provides formulations, methods of treatment, methods of administering, and methods of making that encompass these crystalline insulin-conjugates.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: December 9, 2014
    Assignee: Smartcells, Inc.
    Inventors: Todd C. Zion, Thomas M. Lancaster
  • Publication number: 20140348746
    Abstract: The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.
    Type: Application
    Filed: March 17, 2014
    Publication date: November 27, 2014
    Applicant: VisEn Medical, Inc.
    Inventor: Narasimhachari Narayanan
  • Patent number: 8895699
    Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein the peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting the peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized a-helical structure; and (2) contacting the crosslinked stabilized a-helical structure with MDM2.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: November 25, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Christian E. Schafmeister
  • Patent number: 8889835
    Abstract: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: November 18, 2014
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg, Chien-Hsing Chang
  • Patent number: 8883968
    Abstract: The method for producing a surfactin or a salt thereof according to the present invention comprises the steps of adding an organic solvent containing a branched alkyl alcohol to a culture fluid containing the surfactin or the salt thereof, or to a solution obtained by removing an insoluble component from the culture fluid, and extracting the surfactin or the salt thereof with the organic solvent, wherein the surfactin or the salt thereof is represented by the formula (1): wherein * indicates an optically active center; X is an amino acid selected from leucine, isoleucine and valine; R is a C9-13 alkyl group or a C9-13 branched alkyl group; and M is an alkali metal, an alkaline earth metal, an optionally-substituted amine or the like.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: November 11, 2014
    Assignee: Kaneka Corporation
    Inventors: Masashi Izumida, Hiroaki Kawasaki, Tadashi Moroshima
  • Patent number: 8883964
    Abstract: The invention provides modified collagen and related therapeutic and diagnostic methods.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 11, 2014
    Assignee: The Johns Hopkins University
    Inventors: Michael Yu, Jennifer H. Elisseeff, Allen Yi-Lan Wang, Hyeseung Janice Lee, Xiao Mo
  • Publication number: 20140316105
    Abstract: The present invention is directed to a method of alkylating a thiol group (R—S—H) or seleno group (R—Se—H) in a target molecule wherein the method comprises: reacting a target molecule comprising at least one thiol group with a compound of formula (I) or (II): wherein R is an acetyl group or any other acyl group or is a group comprising any one of: or wherein R in formula (II) can also be an alkyl group; and wherein R? is selected from a group consisting of a hydrogen, a methyl group and an ethyl group.
    Type: Application
    Filed: May 14, 2012
    Publication date: October 23, 2014
    Applicant: Nanyang Technological University
    Inventors: Chuan-Fa Liu, Fupeng Li
  • Patent number: 8859492
    Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.
    Type: Grant
    Filed: May 12, 2012
    Date of Patent: October 14, 2014
    Assignee: MetalloPharm, LLC
    Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
  • Publication number: 20140294902
    Abstract: The invention relates to disulfide-rich peptide molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • Patent number: 8846863
    Abstract: The subject invention pertains to methods of making crosslinked protein-carbohydrate conjugates (CPCCs) and uncrosslinked protein-carbohydrate conjugates (PCCs) that are heat, pH and salt stable. Methods of stabilizing CPCCs and PCCs are also provided. The PCCs and CPCCs formed according to the methods disclosed herein are useful in the food industry and for loading with substances of interest.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: September 30, 2014
    Assignee: University of Tennessee Research Foundation
    Inventor: Qixin Zhong
  • Patent number: 8846864
    Abstract: The present invention relates to a series of compounds useful for effecting purification, in particular for use in purification of synthetic peptides and proteins. The compounds of the invention are particularly efficient at securely anchoring peptides or proteins to a surface and allowing the peptide or protein to become uniformly orientated, thus ensuring that substantially all of the peptide or protein is available for molecular binding to a substrate.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: September 30, 2014
    Assignee: Almac Sciences (Scotland) Limited
    Inventors: David William Anderson, Graham John Cotton, Alastair Mackie Hay, Paul William Armstrong, Ian Wilson
  • Patent number: 8841414
    Abstract: A compound including a cell penetrating peptide (CPP), an elastin-like polypeptide (ELP), and a therapeutic peptide (TP) can be preferentially directed to a target site by applying hyperthermia. The compound can be useful for the treatment of tumors.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 23, 2014
    Assignee: University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III
  • Patent number: 8828542
    Abstract: Nanoparticles can include a core linked to a polymerizable moiety that can be polymerized, cross-linked or cured. The polymerizable nanoparticles can be included in a composition for a polymerization, cross-linking or curing reaction in an amount and disposition sufficient for inhibiting or preventing volume shrinkage during polymerization, cross-linking or curing reaction. Also, the nanoparticles can be included with monomers, dendrimers, oligomers or polymers in the compositions that can be reacted to form a polymerized, cross-linked or cured product.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: September 9, 2014
    Assignee: Korea University Research and Business Foundation
    Inventor: Dong Hoon Choi
  • Patent number: 8816051
    Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via a nucleophilic moiety; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two nucleophilic moieties; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via nuc
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: August 26, 2014
    Assignee: Polytherics Limited
    Inventors: Stephen James Brocchini, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
  • Patent number: 8796420
    Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: August 5, 2014
    Assignee: AvidBiotics Corp.
    Inventors: David W. Martin, Jr., Steven R. Williams
  • Publication number: 20140206842
    Abstract: The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the Synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin.
    Type: Application
    Filed: January 22, 2013
    Publication date: July 24, 2014
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Renukeshwar H. Chandramouli, Rattan Sood, Subbalakshmi Prakash, Susmitha Anand